Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AliviaMax is an ophthalmic solution containing cyclopentolate hydrochloride, a synthetic anticholinergic agent. Developed by Denver Farma, it is primarily used to induce mydriasis (dilation of the pupil) and cycloplegia (paralysis of the ciliary muscle) during diagnostic procedures such as refraction testing and ophthalmoscopic examinations. By competitively blocking muscarinic receptors in the eye, it prevents the contraction of the iris sphincter and the ciliary body muscle. It is typically available in 0.5% and 1% concentrations and is marketed in Argentina for ophthalmic use.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cyclopentolate (Denver Farma).